Founded in 2014 by world leading statistical and human geneticists from the University of Oxford, Genomics has been at the forefront of integrating large-scale genomic data and advanced analytics to transform the future of genomics. By creating the largest genome-wide associate study (GWAS) and genotype-phenotype data resource, and pioneering polygenic risk scores (PRS), Genomics has unlocked new possibilities in disease prediction, drug development, and clinical research.
Genomics’ precision medicine tools and data-driven insights enable biopharmaceutical companies to innovate efficiently, accelerating the discovery and development of drugs with higher success rates. Genomics’ technology-driven solutions are advancing the understanding of disease biology, reducing financial and human costs, and improving the overall efficiency of the drug development pipeline.
AI and Machine Learning: The Future of Drug Discovery
At the core of Genomics’ success is its ability to harness the power of AI and machine learning to analyse vast genetic datasets. This approach enables biopharmaceutical companies to make data-driven decisions.
- Novel Target Discovery: Through AI-powered analysis of genetic variation, Genomics is helping to identify drug targets that are more likely to succeed in clinical trials. This genetics-first enables partners to prioritise targets based on causal genetic evidence, increasing the likelihood of success.
- Biomarker Identification: Genomic insights are enabling the discovery of biomarkers that can be used to predict disease progression, therapeutic response, and clinical outcomes. These biomarkers can guide drug development, optimise patient selection, and improve trial efficiency.
Reducing Risks and Accelerating Development in Life Sciences
One of the greatest challenges in life sciences is the high failure rate of drug candidates in clinical trials. Genomics is helping to mitigate these risks by providing actionable genetic insights that inform every stage of drug development. Here’s how Genomics is enabling life science companies to de-risk and accelerate the process:
- Indication Expansion and Repurposing: By leveraging genetic data, Genomics enables companies to explore shared biology across multiple diseases, allowing for the identification of therapies that can address multiple indications. This approach leads to faster time-to-market and the repurposing of existing drugs to new indications.
- Polygenic Risk Scores (PRS): Enabling partners to refine patient populations, identifying those who are most likely to benefit from a particular treatment. By using genetic data to better select patient cohorts, companies can reduce trial size, duration, and cost, while still ensuring statistical power.
- Event Rate and Progression Prediction: By analysing genetic factors that influence disease progression, Genomics enables more accurate predictions of event rates, which could translate to smaller, more efficient trials.
- Therapeutic Response Prediction: Using genetic data, Genomics can enable partners to predict how many patients will respond to specific treatments. This allows for more targeted drug development, increasing the chances of success and improving patient outcomes.
For companies looking to accelerate their drug development processes and reduce risks, Genomics offers cutting-edge, AI-powered genomics tools that can help guide target discovery, patient selection, and clinical trials. Explore how Genomics is driving the future of genomics and empowering the next generation of precision medicine.
Find out more at https://www.genomics.com/
Contact us at partnerships@genomics.com
About Drug Discovery Innovation Programme 2025
The Drug Discovery Innovation Programme is an exclusive, invitation-only event designed to connect leading scientists, researchers, and industry pioneers in a dynamic and collaborative environment.
Join us in person to gain insights from top experts in drug discovery and development, exploring the latest breakthroughs, emerging technologies, and innovative approaches shaping the future of the industry. With a forward-thinking agenda covering small molecule discovery, biologics, AI-driven translational medicine, and regulatory insights, DDIP 2025 will feature tailored sessions led by global leaders.
Bringing together visionaries from Johnson & Johnson Innovative Medicine, Regeneron Pharmaceuticals, Amgen, Novo Nordisk, AbbVie, GSK, Exelixis, Insilico Medicine, and many more, this event is your opportunity to expand your knowledge, network with key stakeholders, and accelerate your drug development journey.